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Grape polyphenols have shown a promising role in the modulation of metabolic syndrome 26 
(MetS), mostly in animal models. However, clinical studies are scarce and they usually 27 
only consider a fraction of polyphenols, ignoring the non-extractable polyphenols (high 28 
molecular weight compounds or associated with macromolecules such as dietary fibre). 29 
This study aimed to evaluate the effect of grape pomace, rich in both extractable and non-30 
extractable polyphenols, on markers of MetS. Fifty subjects (22 women) aged 20-65 with at 31 
least two MetS factors were randomly assigned to the product (daily dose of 8 g of dried 32 
grape pomace) or to the control group in a 6 weeks crossover design with a 4 weeks wash-33 
out. Samples were collected at the beginning and at the end of both periods; half of the 34 
participants were subjected to an Oral Glucose Tolerance Test at the beginning and the end 35 
of the supplementation period. Grape pomace supplementation significantly improved 36 
fasting insulineamia (p<0.01), without affecting other cardiometabolic risk parameters. A 37 
tendency towards an improvement in postprandial insulineamia was observed, particularly 38 
in those subjects with higher fasting insulin levels. Therefore, supplementation with grape 39 
pomace may be a strategy for improving insulin sensitivity in subjects at high 40 
cardiometabolic risk. 41 










AUC: area under the curve. 50 
BMI: body mass index. 51 
DF: dietary fiber. 52 
HDL: high-density lipoprotein. 53 
HOMA-IR: homeostatic model assessment-insulin resistance. 54 
LDL: low-density lipoprotein. 55 
MetS: metabolic syndrome. 56 


















Metabolic Syndrome (MetS) is a cardiometabolic situation that comprises the combination 73 
of several risk factors (abdominal obesity, hyperglycaemia, hypertension and dyslipidemia, 74 
among others) associated with a sedentary lifestyle. Although it is not a disease per se, 75 
MetS may lead to the onset of type 2 diabetes or different cardiovascular pathologies 1. The 76 
main underlying mechanism in MetS is insulin resistance, combined with increased 77 
oxidative stress and chronic low-level inflammation 2, 3. It has been estimated that the 78 
prevalence of MetS is 20-30% of adults in developed countries4; therefore, finding new 79 
strategies for tackling MetS is a relevant challenge. 80 
Within this context, there is particular interest in the identification of nutritional strategies 81 
that, as previous step to drug approach, may ameliorate the disturbances present in MetS. 82 
Polyphenols, a diverse family of plant secondary metabolites widely spread in plant foods, 83 
are promising agents in that sense. In particular, there is cumulative evidence through in 84 
vitro and preclinical studies that polyphenols may be able to regulate some of the 85 
physiological processes altered in MetS by different mechanisms of action 5-11: 86 
modification of postprandial glycaemia due to interactions with intestinal glucosidases and 87 
glucose transporters; improvement of insulin and adiponectin signalling pathways; 88 
reduction of oxidative stress and inflammation; hypotensive effect; hypolipidemic effect by 89 
repressing intestinal lipid absorption, triglyceride content in skeletal muscle and 90 
chylomicron/VLDL secretion.   91 
Many studies on the role of polyphenols in the modulation of MetS have been performed 92 
with berries due to their high polyphenol content, mostly proanthocyanidins and 93 
anthocyanins. Thus, beneficial effects on inflammation markers, lipid profile or insulin 94 
resistance have been reported after the supplementation with wild blueberries, ellagitannin-95 
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rich berries or ginseng berry, respectively 12-14. More specifically, grape derived products 96 
such as grape seed extracts have shown beneficial effects in the same sense 7. However, 97 
these extracts only contain a fraction of polyphenols -the extractable polyphenols- while 98 
their derived residues present a high amount of the so-called non-extractable polyphenols or 99 
macromolecular antioxidants. They are high molecular weight compounds or compounds 100 
associated with macromolecules such as dietary fibre, with promising health-related 101 
properties15. Grape pomace is a material commonly discarded during the wine-production 102 
process with a high content in both extractable and non-extractable polyphenols16, being 103 
therefore a very interesting product to be tested for the effect of its polyphenols as a whole 104 
in the modulation of MetS  as well as an important opportunity for the environmental 105 
sustainability. In addition, although a significant number of animal studies have explored 106 
the effect of grape polyphenols on MetS markers, clinical trials on the subject have been 107 
much limited and with contradictory results 17.  108 
Therefore, the aim of this study was to evaluate the capacity of a long term supplementation 109 
at nutritional doses of grape pomace (containing both extractable and non-extractable 110 
polyphenols) to modulate metabolic disturbances present in subjects at cardiometabolic risk 111 
related to MetS. 112 
EXPERIMENTAL 113 
Dietary supplement  114 
This study was performed with a nutritional supplement constituted by dried and milled 115 
grape (Vitis vinifera L., cv Tempranillo) pomace. It was collected fresh -at the moment of 116 
wine devating- from Roquesan Wineries (Quemada, Burgos, Spain), being later transported 117 
at -20ºC, freeze-dried, ground to a particle size of 0.5 mm and sealed in monodoses (8 g). 118 
These monodoses were stored at -20ºC until the beginning of the study, three months later. 119 
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We had previously verified that freeze-dried grape pomace, under freezing conditions, kept 120 
a constant polyphenols composition; moreover, in case some degradation took place, this 121 
would affect to the minor extractable fraction of polyphenols and not to the major non-122 
extractable polyphenols.  Prior to the intervention study, standard microbiological (E.coli β-123 
glucuronidase, L. monocytogenes, Salmonella spp., viable aerobes at 30ºC and fungi/yeast) 124 
and metal (Pb, Cd, Ni, Zn, As and Sb) analyses were carried out to guarantee the safety of 125 
the product. 126 
Dried grape pomace was characterized by a high polyphenol content (29.63 %), particularly 127 
non-extractable polyphenols or macromolecular antioxidants (23.44 %), as well as a by a 128 
very high content in dietary fiber (68.23 %), mostly insoluble (65.65 %). More information 129 
on the composition of the product, as well as the methods used for its evaluation, are 130 
provided as Electronic Supplementary Information (Table S1). Besides, the detailed 131 
polyphenol composition of this product -combined with pomegranate pomace- was reported 132 
elsewhere16. It should be remarked that, since this dietary supplement is not an extract, but 133 
the whole grape pomace matter only subjected to drying and milling, other studies have 134 
described the composition of such material 18 . 135 
Subjects and study design 136 
This study was a randomized cross-over controlled clinical trial approved by the Ethics 137 
Subcommittee of the Spanish National Research Council (CSIC), Madrid, Spain 138 
(2016/12/13) and the Ethics Committee for Clinical Research of the University Hospital 139 
Puerta de Hierro-Majadahonda, Majadahonda, Spain (2016/12/02). It was registered in the 140 
Clinical Trials database with the identifier NCT03076463. The study was conducted 141 
between December 2016 and July 2017. All the subjects signed an informed consent form 142 
agreeing to participate in the study. 143 
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Subjects were recruited via poster advertisements and mailing sent to academic, social, 144 
sanitary, and research institutions, in addition to personal contacts in Madrid, Spain. 145 
Inclusion criteria for the study were to be aged 18-70 years, apparently healthy and to fulfill 146 
at least two of the following requirements, based on official criteria for the diagnose of 147 
MetS 1: Body Mass Index > 25 kg/m2; fasting glucose ≥ 100 mg/dL; HDL-cholesterol ≤ 50 148 
mg/dL in women and 40 mg/dL in men; triglycerides ≥ 150 mg/dL; systolic pressure ≥ 130 149 
mmHg or  diastolic pressure ≥ 85 mmHg. Exclusion criteria were: diagnose or medication 150 
for cardiometabolic pathologies; being pregnant or lactating; current or close participation 151 
in any other dietary intervention study. 152 
The study included two different 6 week periods, separated by a 4 weeks wash-out: a 153 
supplementation period (daily supplementation with 8 g of product described above 154 
suspended in water) and a control period (no appropriate placebo was found). Since it was a 155 
cross-over design, subjects were randomly allocated to two groups, each one of them 156 
starting by one of the periods. There was a difference of 10 weeks (6 of supplementation 157 
and 4 of wash-out) between those subjects starting with the control period and those with 158 
the supplementation period; this lag-time does not affect the polyphenol composition of the 159 
product, as explained above. Volunteers were instructed to follow their habitual diet and 160 
daily activities, as well as to store the monodoses of the product under freezing conditions. 161 
Samples collection and measurements were performed at the beginning and at the end of 162 
each one of these periods. Besides, at the beginning and at the end of the supplementation 163 
period, half of the participants were subjected to a fasting OGTT (oral glucose tolerance 164 
test) that consisted of ingesting 75 g of glucose in 200 mL of water; therefore, glucose 165 
homeostasis parameters were evaluated only in these subjects. In order to limit the potential 166 
effect of a high dietary polyphenol consumption close to the visits, 72 h prior to each visit 167 
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day, the subjects were required to refrain from consumption of polyphenol-rich foods such 168 
as wine, coffee, tea, cocoa, whole bread, virgin oil olive, nuts, legumes and certain fruit and 169 
vegetables such as berries or artichoke. A detailed list was provided to the volunteers. 170 
Sample size calculation 171 
The primary outcome variable for sample size calculation was the modification in HOMA-172 
IR  (homeostatic model assessment for insulin resistance) index. In particular, power 173 
calculations were based on a 30% reduction in HOMA-IR (or 10% increase in QUICKI, 174 
quantitative insulin-sensitivity check index, based on the same parameters) following 175 
previous nutritional clinical trials in subjects with impaired glucose tolerance supplemented 176 
with polyphenol-rich materials 19. A sample size of 40 was calculated as sufficient to detect 177 
this change with 95% power and an alpha value of 0.05, using published variances of this 178 
parameter 19. This number was increased to 50 to ensure statistical power was sufficient 179 
even if an important proportion of the subjects failed to complete the trial. 180 
Sampling and biochemical analysis 181 
Fasting blood samples were collected at the beginning and the end of each period between 182 
8:00 and 10:00 h and after at least 10 h of fasting. During the OGTT study, blood was 183 
collected at times 0, 30, 60 and 120 min. Serum and plasma were obtained after 184 
centrifugation at 1000 g for 15 min and stored at -80 ºC. First morning urine was collected 185 
and stored in aliquots at -80ºC. 186 
The following parameters were measured by different automatic analyzers (Siemens 187 
Healthineers, Tarrytown, NY, USA): ferritin by ADVIA Centaur XP; fibrinogen by 188 
Sysmex C5-5100 Hemostasis System; serum total cholesterol, HDL cholesterol, LDL 189 
cholesterol, triglycerides, iron, AspAT (aspartate aminotransferase), ALT (alanine 190 
aminotransferase), and high-sensitive plasma C reactive protein by ADVIA Chemistry XPT 191 
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System; blood erythrocytes, hemoglobin, hematocrit, MCV (mean corpuscular volume), 192 
MCH (mean corpuscular hemoglobin), MCHC (mean corpuscular hemoglobin 193 
concentration), platelets, and MPV (mean platelet volume) by ADVIA 2120i Hematology 194 
system. The following analytes were determined by commercial ELISA kits according to 195 
manufacturer instructions: plasma insulin and leptin (Merck-Millipore, Burlington, MS, 196 
USA), and serum soluble transferrin receptor (DRG Instruments, Germany). Uric acid was 197 
measured in plasma and urine by a commercial kit (Spinreact, S.A., Sant Esteve de Bas, 198 
Spain). Determinations in urine were normalized by creatinine concentration, measured by 199 
a commercial kit (Cromatest, Linear Chemicals S.L., Montgat, Spain). Fasting and 200 
postprandial blood glucose was determined by applying the enzyme electrode method using 201 
a Free Style Optimum Neo blood glucose meter from Abbott (Chicago, IL, USA). 202 
The areas under the curves (AUCs) for glucose and insulin were estimated using the 203 
trapezoidal function 20. Insulin resistance was estimated with the HOMA-IR ([glucose 204 
(mg/dL)*insulin (µU/mL)]/405) and insulin sensitivity was estimated by the QUICKI index 205 
(1/[log insulin (µU/mL)+log glucose (mg/dL)]). 206 
Blood pressure and anthropometric determinations 207 
Blood pressure was measured at the beginning and the end of each period between 8:00 and 208 
10:00 h in a quiet temperature-controlled room using an automated digital oscillometric 209 
device (Omron model M6 Comfort, Omron Corporation, Tokyo, Japan), and a mean of two 210 
readings was taken. Height, body weight and abdominal and hip perimeter were measured. 211 
Body composition was assessed by using a tetrapolar bioimpedance system (Tanita BC601, 212 
Arlington heights, IL, USA), including the following parameters (%): BMI, % body fat, % 213 
body water, muscle mass and bone mass.  214 
Intestinal transit evaluation 215 
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At the end of the supplementation period, the subjects fulfilled a questionnaire with three 216 
questions (answered in a scale 0-10): “Did you perceive some modification in the number 217 
of bowel movements/amount excreted/stool consistency since you started to consume this 218 
product?” 219 
Dietary assessment 220 
Diet information was collected throughout the study via three 24 h dietary questionnaires 221 
(two for working days and one for weekend) applied before the study, and during the two 222 
periods (control/grape pomace). Data were processed for each 3 day-period by the DIAL 223 
System (Universidad Complutense de Madrid, Spain). Additionally, from the second visit 224 
the subject answered the question “Have you modified your physical activity since the last 225 
visit? If so, did you increase or decrease it?”.   226 
Statistical analysis 227 
Data were analyzed with the statistical SPSS IBM 24 package for Windows. First, outliers 228 
(>1.5 IQR) and extreme values (>3.0 IQR) were identified using box-and-whiskers plots, 229 
and extreme values were excluded from the results. Second, the possible effect of 230 
randomization (group assignment) was evaluated; for this, a t-Student test for independent 231 
variables was performed for basal values for each of the MetS factors between both groups 232 
(control and grape pomace), observing no statistical differences between groups. Therefore, 233 
data for all subjects when belonging to the control or to the grape pomace group, 234 
independently of the assignation order, were processed together. Subsequently, normal data 235 
distribution was evaluated based on kurtose coefficient (between -1 and +1) and, when it 236 
was not fulfilled, log transformation was performed (log + 1 when values were below 1). 237 
Finally, specific statistical analyses were applied for the different datasets: a) for diet 238 
evaluation (corresponding to three periods for each subject), analysis of variance (ANOVA) 239 
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followed by Tukey’s test were applied; b) for glucose homeostasis measurements, t-student 240 
test for paired samples was applied; c) for fasting measurements, the Mixed Linear Model 241 
for repeated measures was applied and the effects of treatment (control or grape pomace), 242 




The detailed CONSORT diagram of this clinical trial is shown in Figure 1. Briefly, from a 247 
total of 234 subjects interested in the study, 48 started the first period. There was an 248 
additional recruitment during the development of this period with three additional subjects 249 
participating in only one arm of the study in order to increase the number of volunteers that 250 
consumed the supplement; it was considered this was a better solution than having three 251 
subjects prolonging the study until a different season. Therefore, considering drop-outs 252 
during the study, data from a total of 49 subjects were analyzed. Overall, there was a high 253 
adherence to the study, with one drop-out due to medical reasons (diagnose of severe 254 
dislypidaemia) and two for sensory reasons. 255 
The age of the subjects was 20-65, with a mean value of 42.6 (SE 1.6). Twenty-two 256 
participants were females. The mean number of risk factors was 2.8 (SE 0.1), with a 63% of 257 
the subjects fulfilling the official criterion for the diagnosis of MetS (at least three factors). 258 
The distribution of the different risk factors among the subjects is shown in Table 1; 259 
overweight/obesity, hypertension and hyperglycaemia were the most common risk factors 260 
among them. 261 
The comparative evaluation of the subjects’ diet (before the study and during the two 262 
periods) showed that there was no significant modification in any of its main parameters 263 
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(caloric content, macronutrient intake, selected micronutrient intake), as shown in Table S2. 264 
Additionally, although no detailed physical activity questionnaire was performed, 80% of 265 
the subjects did not modify their physical activity during the study based on a subjective 266 
perception (Table S3). Therefore, the potential effects observed during the supplementation 267 
period could be attributed to this supplementation.   268 
Glucose homeostasis 269 
Results for glucose and insulin levels during the OGTT are shown in Table 2. Fasting and 270 
postprandial glucose during the different sampling times were similar before and after the 271 
supplementation period. In contrast, basal insulin was significantly decreased (P < 0.01) 272 
after the supplementation with grape pomace. A non-significant tendency towards lower 273 
AUC 0-120 min after the supplementation (3,416 SEM 721 µU/mL x min), as compared 274 
with the value before supplementation (4,247 SEM 816 µU/mL x min), was observed. 275 
Moreover, when the subjects were stratified according to their 120 min insulin values (with 276 
a cut-off value of 50 µU/mL), it was observed that, after the treatment, a 93% of subjects 277 
with initial insulin values below 50 µU/mL kept within that range -as expected- but a 25% 278 
of the subjects with initial insulin values above 50 µU/mL moved below that value after the 279 
supplementation; these tendencies should be evaluated in further studies in order to confirm 280 
whether they actually reach significance. Insulin sensitivity and resistance indexes were 281 
also calculated, from fasting glucose and insulin values (Table 3). The supplementation 282 
with grape pomace caused a significant decrease (P < 0.01) in HOMA-IR, concomitant to a 283 
significant (P < 0.05) increase in QUICKI index; none of them were observed during the 284 
control period.  285 
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Leptin was also measured at fasting time and 120 min, as hormone closely related with 286 
satiety and insulin sensitivity (Figure 2). Values at both sampling times as well as before 287 
and after supplementation with grape pomace did not exhibit significant differences.  288 
Finally, plasma uric acid was measured between fasting state and 120 minutes after glucose 289 
overload, with no significant differences between either any of the sampling times or the 290 
treatments (data not shown). 291 
Glucose homeostasis, as indicated above, was only evaluated in half of the subjects; 292 
therefore, these results only correspond to the pre-and post-supplementation samples, 293 
without the strength provided by the cross-over design. Nevertheless, it should be stated 294 
that, as shown below, there were no significant modifications during the control period in 295 
all the parameters measured according to the cross-over design. It could be expected that 296 
this was also the case for glucose homeostasis, although further studies should confirm this. 297 
Cardiometabolic risk factors 298 
Table 4 shows the evolution in cardiometabolic risk factor during the study. No significant 299 
time-treatment effect was observed. During both control and supplementation periods, a 300 
significant (P < 0.05) decrease in fibrinogen was observed. Also, there was a slight 301 
tendency towards the decrease of total cholesterol and LDL cholesterol, which was higher 302 
in the supplementation period. Regarding uric acid, a tendency towards decrease was 303 
observed in the supplementation period; nevertheless, uric acid values were higher in this 304 
period than in the control period.  305 
Iron status markers 306 
Results for hemogram parameters and iron status are shown in Table 5. No significant 307 
time-treatment effect was observed. During both control and supplementation period, 308 
significant (P < 0.05) decreases in hematocrit and erythrocytes distribution index, as well as 309 
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increases in MCHC and MPV were observed. A tendency towards an increase in platelets 310 
and decrease in ferritin was observed in both periods, although slightly higher in the 311 
supplementation period.  312 
Anthropometric measurements 313 
Table 6 indicates the results for anthropometric measurements. No significant differences 314 
were observed either for general parameters (Body Mass Index, abdominal perimeter, 315 
waist-to-height ratio, waist-to-hip ratio, metabolic age, visceral fat index), body 316 
composition (fat, muscle bone mass, water) or abdominal composition (fat, muscle). 317 
Intestinal transit 318 
Intestinal transit was improved after grape pomace supplementation based on subjective 319 
perception. Thus, a 57% of the subjects reported some increase in the total number of 320 
depositions (with 26% rating between 8 and 10) and a 54% reported some increase in the 321 
amount of feces excreted (with 21% rating between 8 and 10). Regarding consistency, 36% 322 
of the subjects observed a tendency towards more liquid deposition although not implying a 323 
drastic change in consistency (rates between 6-8); nevertheless, a 20% of the subjects 324 
reported that grape pomace supplementation caused much more liquid stools (rates 9 and 325 
10), while 16% observed an effect towards more solid depositions (rates below 5). 326 
DISCUSSION  327 
This study aimed to evaluate the potential of grape pomace to modulate parameters related 328 
to MetS in subjects at high cardiometabolic risk. Despite the heterogeneity of the subjects 329 
participating in the study –intrinsic to the definition of MetS-, it should be remarked that 330 
they presented overweight, hypertension and hyperglycaemia as the most common cluster 331 




The specific approach of this study was to perform a supplementation with grape pomace, 334 
rich in both extractable polyphenols and non-extractable polyphenols, commonly ignored in 335 
studies of the topic15. The natural combination of both polyphenol classes in a single matrix 336 
intrinsically associated with dietary fiber is a particular characteristic of grape pomace, 337 
which therefore differs from the composition of other grape derived products 21. 338 
Conversely, this limits the comparison of this clinical trial with others in the field of grape 339 
and MetS -a topic on which a narrative review 22 and a systematic review 17 were recently 340 
published- since clinical trials with grape pomace have been much scarce 23, 24. Moreover, 341 
the approach selected here means a complete use of the whole material generated during 342 
wine processing, in contrast to others based on polyphenol-rich extracts from grape 343 
pomace, leaving still a substantial amount of discarded material.  344 
The supplementation -based on subjective perception with intrinsic limitations- seemed to 345 
improve intestinal transit, what was expected from its insoluble dietary fibre content 25 and 346 
previously reported for a grape pomace derived product 23. The most remarkable effect was 347 
that daily consumption of grape pomace in subjects at high cardiometabolic risk 348 
significantly decreased fasting insulineamia. Moreover, the supplementation significantly 349 
improved several insulin sensitivity indexes; in the case of HOMA-IR, the subjects moved 350 
from original values corresponding to a situation of insulin resistance and MetS 26 to 351 
normal HOMA-IR values. Interestingly, a tendency towards the regulation of postprandial 352 
insulin sensitivity was also observed, especially in subjects with the highest insulin basal 353 
values (> 50 µU/mL). These effects may be related to the processes described in other 354 
mechanistic studies on the role of polyphenols in insulin metabolism. In particular, several 355 
animal studies have reported that grape, other berries or cocoa (all with a polyphenol 356 
profile very similar to that of grape pomace) are able to modulate insulin production and 357 
16 
 
degradation 7 as well as to affect insulin signaling. This latter effect may take place by 358 
decreasing serine-phosphorylated levels of the insulin receptor substrate 1 and preventing 359 
the inactivation of the glycogen synthase kinase 3/glycogen synthase pathway in the liver 27 360 
or by increasing the expression of fokhead box protein 1 (FOXO1) and peroxisome 361 
proliferators-activated receptor gamma (PPAR γ) in muscle 13. A recent study in subjects 362 
with at least one component of MetS supplemented with a higher dose of grape pomace (20 363 
g/day) reported a significant improvement in postprandial insulinaemia24. In contrast, a 364 
recent clinical trial with a red wine polyphenol extract did not observe any improvement in 365 
insulin sensitivity in obese subjects after an 8 weeks supplementation 28. This discrepant 366 
result may be due either to differences in the studied population or in the product provided. 367 
A previous acute study with grape and pomegranate pomaces in subjects with abdominal 368 
obesity showed a non-significant tendency towards the improvement of insulin sensitivity 369 
when the product was provided 10 h before performing an OGTT (Pérez-Ramírez et al., 370 
submitted). It was suggested that this tendency could be due to the microbial-derived 371 
polyphenol metabolites as main responsible of the biological effects of polyphenols 29, 372 
comprising also non-extractable polyphenols 30. Nevertheless, it is remarkable that this 373 
potential effect of fruit pomaces on insulin regulation, observed after an acute intake, was 374 
more clearly observed here after a chronic intake. This connects with the idea that 375 
polyphenols exert subtle modifications that need long period to be observed in biochemical 376 
risk parameters 31.  377 
Leptin was also measured in samples from fasting time and 120 min in the OGTT. 378 
Resistance to this hormone via impairment in its signaling or its transport towards the brain, 379 
thus avoiding its anorexigenic effects, has been reported as an additional metabolic 380 
alteration present in MetS 32. Interestingly, studies in rats either with pure polyphenols or 381 
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polyphenol-rich extracts have shown that these compounds are able to counteract leptin 382 
resistance 33. The participants in this study exhibited a tendency towards leptin resistance, 383 
with basal values about 25 ng/mL, concordant with their profile of overweight/obesity 34. 384 
Slightly lower leptin values, although non-statistically significant, were observed 120 min 385 
after the glucose overload; some studies have reported a significant decrease of leptin at 386 
this time 35, while others did not find significant differences in this hormone during the 387 
postprandial period suggesting other regulatory mechanisms for satiety 36. Anyway, grape 388 
pomace supplementation did not alter either fasting or postprandial leptin. Studies reporting 389 
an effect of polyphenol supplementation on leptin levels in animal models indicate this 390 
activity takes place by reducing adipose tissue and improving hypothalamic leptin signaling 391 
37. Moreover, a decrease in leptin levels was reported in overweight subjects after 392 
supplementation with a polyphenol-rich extract.  Nevertheless, these studies were focused 393 
on polyphenol classes different to those present in the grape pomace used here, what may 394 
explain the lack of modifications in this marker.  395 
No significant modifications were observed in all the other parameters evaluated 396 
(cardiometabolic risk, anthropometry). This contrasts with previous studies reporting 397 
beneficial effects on lipid profile in hypercholesterolemic subjects supplemented with a 398 
product derived from grape pomace 23 or the ability of polyphenols to decrease uric acid 399 
levels 38. This discrepancy might be associated to the specific characteristics of subjects of 400 
this study, which exhibited overweight/obesity. In this way, it was recently reported that 401 
overweight subjects exhibited lower levels of phase II polyphenol metabolites, i.e. the 402 
compounds responsible for their biological activities, after a repeated supplementation with 403 
a grape seed extract, as compared with lean individuals 39. Therefore, it may be 404 
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hypothesized that lower levels of circulating polyphenol metabolites in the present study 405 
would decrease their potential biological effects.  406 
Also, some of the discrepancies between this study and previous ones with grape products 407 
may be derived from the fact that a specific approach of the present study was to use a 408 
realistic dose (8 g/day, equivalent to less than 100 g fresh grapes/day), which could be 409 
easily incorporated in a common diet. In contrast, other studies with grape extract or grape 410 
pomace, reporting effects in parameters such as hypertension or fasting glucose used higher 411 
doses (20g/d of grape pomace or 2 servings/d of grape) 24, 40 or less nutritional approaches 412 
(6 pills/day) 41. Indeed, a recent review concluded that a dose of 150-600 mg grape 413 
products/kg body weight day was needed in order to obtain favorable effects on marker of 414 
MetS 22. This calculation applied to the present study yields a dose of 13-52 g/d in the 415 
subjects participating in this study (mean weight, 89 kg). Nevertheless, this review did not 416 
include any clinical trial with grape pomace, so there is still much research to be done 417 
regarding this grape product with the specific composition described above. 418 
Additionally, we determined several haematological and biochemical parameters related 419 
with iron bioavailability, as it is widely known that polyphenolic compound can reduce iron 420 
absorption 42, but there were no effects of the supplementation, which should be interpreted 421 
considering the low dose of the supplement, the experimental period, and the characteristics 422 
of the subjects who exhibited adequate iron stores (as determined by serum ferritin). 423 
Finally, it should not be disregarded that, as a recent review highlighted 43, only a 424 
combination of a polyphenol-rich diet including all the diversity of dietary polyphenols, 425 
seems to be able to simultaneously counteract all the features present in MetS. Within this 426 
context, the role shown here of grape pomace on the modulation of insulin would 427 
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contribute to the overall health-related properties of polyphenols, where the specific 428 
contribution of macromolecular antioxidants should also be considered. 429 
CONCLUSIONS 430 
A cross-over randomized clinical trial was performed in subjects with at least two factors of 431 
MetS. A 6-week supplementation with a realistic dose (8 g/day) of grape pomace, rich in 432 
both extractable and non-extractable polyphenols, significantly improved fasting 433 
insulineamia, without affecting other cardiometabolic risk parameters. A tendency towards 434 
an improvement in postprandial insulineamia was observed, particularly in those subjects 435 
with higher fasting insulin levels. These results show a promising role of grape pomace as 436 
coadjuvant for keeping standard insulin values, which should be further studied in subjects 437 
exhibiting hyperinsulineamia.  438 
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Figure 1.  CONSORT flow diagram trough the phases of a randomized, cross-over clinical 
trial on the effects of grape pomace in subjects at high cardiometabolic risk  
Figure 2. Plasma leptin in subjects at high cardiometabolic risk before and after 6 weeks of 
daily supplementation with grape pomace, in fasting state (dark grey) and 120 min after an 
oral glucose overload (black) Data are represented as mean with their standard errors. No 






Table 1. Metabolic syndrome risk factors among participants in the clinical trial with grape 
pomace besides overweight (55% of the subjects) or obesity (45% of the subjects).  
Risk factor Number of 
participants 
Blood pressure 32
  Alone  5 
  + Glucose 11 
  + Glucose + HDL-cholesterol 7 
  + Glucose + triglycerides 2 
  + HDL-cholesterol 4 
 + Triglycerides 3 
Glucose 7
  Alone 4 
  + HDL-cholesterol 2 
  + Triglycerides 1 
HDL-cholesterol alone 8
Triglycerides alone 1
Simultaneous five risk factors 1
Total     49
Cut-off values: Glucose ≥ 100 mg/dL; HDL-cholesterol ≤ 50 mg/dL female, ≤ 40 mg/dL 
male; triglycerides, ≥ 150 mg/dL; systolic blood pressure ≥ 130 mmHg or diastolic blood 
pressure ≥ 85 mmHg; BMI ≥ 25 kg/m2. 
27 
 
Table 2. Plasma glucose and insulin during an Oral Glucose Tolerance Test in subjects at 
high cardiometabolic risk supplemented with grape pomace for 6 weeks 
 Glucose Insulin 
 0 weeks 6 weeks 0 weeks 6 weeks 
 Mean SEM Mean SEM Mean SEM Mean SEM
Concentration1     
  0 min 98 2 100 2 8.5 0.8 5.5** 0.9
  30 min 157 6 161 6 59.8 8.2 66.7 8.7
  60 min 153 10 152 8 80.0 10.7 82.3 10.6
  120 min 109 7 104 5 61.8 12.8 50.8 11.1
AUC     
  0-30 min 3,926 136 3,955 120 1,062 139 1,095 139
  0-60 min 7,616 318 7,655 270 2,687 338 2,623 335
  0-120 min 12,471 443 12,388 373 4,247 816 3,416 721
1 Glucose, mg/dL; insulin, µU/mL; AUC (glucose), mg/dL x min; AUC (insulin), µU/mL x 
min. ** Time effect, P < 0.01. Comparisons were performed using t-test for paired samples. 
28 
 
Table 3. Parameters of insulin sensitivity in subjects at high cardiometabolic risk 
supplemented with grape pomace for 6 weeks.  
 
 Control period Supplementation period 
 0 weeks 6 weeks 0 weeks 6 weeks 
 Mean SEM Mean SEM Mean SEM Mean SEM 
HOMA-IR 1.8 0.1 2.1 0.2 2.1 0.4 1.4** 0.3 
QUICKI 0.35 0.004 0.35 0.004 0.35 0.007 0.42* 0.09 
 
 * P < 0.05; ** P < 0.01. Comparisons were performed using t-test for paired samples. 
HOMA-IR, homeostatic model assessment- insulin resistance; QUICKI, quantitative 
insulin sensitivity check index 
29 
 
Table 4. Cardiometabolic markers in subjects at high cardiometabolic risk supplemented with grape pomace for 6 weeks.  
 Control period Supplementation period 
 0 weeks 6 weeks 0 weeks 6 weeks 
 Mean  SEM Mean SEM Mean SEM Mean SEM 
Lipid profile         
  Total cholesterol (mg/dL) 202 28 195 26 201 29 190 27 
  HDL cholesterol (mg/dL) 50 13 49 7 47 7 48 7 
  LDL cholesterol (mg/dL) 124 17 118 15 121 17 112 16 
  Triglycerides (mg/dL) 143 20 137 21 147 21 150 21 
Blood pressure         
  Systolic (mmHg) 118 17 117 17 118 17 120 17 
  Diastolic (mmHg) 82 11 82 12 82 12 84 12 
Others         
  Plasma uric acid (mg/dL) 5.8 0.8 5.9 0.8 6.0 0.8 6.0 0.8 
  Urine uric acid (mg/g creatinine) 413 68 422 64 490 70 460 66 
  Fibrinogen (mg/dL) 351 47 318* 46 341 48 332* 47 
  High sensitive C reactive protein 0.3 0.07 0.4 0.07 0.3 0.07 0.4 0.07 
  AspAT (U/L) 21.9 3.1 20.1 3.0 22.6 3.2 21.4 3.1 
  ALT (U/L) 25.8 3.6 22.7 3.5 25.6 3.6 24.9 3.6 
  AspAT, asparte aminotransferase; ALT, alanine aminotransferase.* indicates time effect (P < 0.05) 
30 
 
Table 5. Hemogram and iron status in subjects at high cardiometabolic risk supplemented with grape pomace for 6 weeks.  
 Control period Supplementation period 
 0 weeks 6 weeks 0 weeks 6 weeks 
 Mean  SEM Mean SEM Mean SEM Mean SEM 
Hemogram         
  Erythrocytes (106/µL) 5.0 0.1 4.9 0.1 5.0 0.1 4.9 0.1 
  Hemoglobin (g/dL) 15.0 0.2 14.9 0.2 15.0 0.2 14.8 0.2 
  Hematocrit (%) 45.4 0.5 44.7* 0.4 45.1 0.5 43.8* 0.5 
  MCV (fl) 90.7 0.7 91.0 0.7 90.0 0.7 90.1 0.7 
  MCH (pg) 30.0 0.3 30.4 0.3 29.8 0.3 30.5 0.3 
  MCHC (g/dL) 33.1 0.1 33.4* 0.1 33.1 0.1 33.9* 0.1 
  Erythrocytes distribution index (%) 13.4 0.1 12.9* 0.1 13.4 0.1 13.2* 0.1 
  Platelets (103/µL) 262 10 255 9 278 10 259 9 
  MPV (fl) 9.1 0.1 9.6* 0.1 8.9 0.1 9.0* 0.2 
Iron status         
  Iron (µmol/L) 17.3 0.9 15.9 0.8 16.0 0.8 15.0 0.7 
  Transferrin (g/L) 2.9 0.1 2.8 0.1 2.9 0.05 2.8 0.1 
  TIBC (µmol/L) 73.8 1.6 71.3 1.3 72.6 1.2 71.1 1.4 
  Transferrin saturation (%) 23.9 1.3 22.8 1.3 23.3 1.1 21.8 1.2 
  Soluble transferrin receptor (µg/mL) 0.9 0.04 0.9 0.05 1.0 0.05 1.1 0.05 
  Ferritin (ng/mL) 114.3 13.2 109.6 12.0 121.5 14.4 111.2 12.0 
MCV, mean corpuscular volume; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration; MPV, 
mean platelet volume; TIBC, total iron-binding capacity.* indicates time effect (P < 0.05) 
31 
 
Table 6. Anthropometric measurements in subjects at high cardiometabolic risk 
supplemented with grape pomace for 6 weeks.  
 Control period Supplementation period 
 0 weeks 6 weeks 0 weeks 6 weeks 
 Mean  SEM Mean SEM Mean SEM Mean SEM 
General parameters         
  Body Mass Index (kg/m2) 30.6 0.7 30.5 0.7 30.9 0.8 30.9 0.8 
  Abdominal perimeter (cm) 102.9 1.8 103.0 1.9 102.6 1.8 102.4 1.8 
  Waist-to-height ratio 0.6 0.01 0.6 0.01 0.6 0.01 0.6 0.01 
  Waist-to-hip ratio 0.9 0.01 0.9 0.01 0.9 0.01 0.9 0.01 
  Metabolic age 49.6 1.8 49.4 1.9 49.8 1.9 4.7 1.9 
  Visceral fat index 10.7 0.7 10.8 0.7 10.7 0.7 10.5 0.7 
Whole body bioimpedance         
  Fat (%) 32.8 1.3 32.3 1.3 32.7 1.3 32.5 1.4 
  Muscle (kg) 56.1 1.6 56.2 1.6 56.0 1.5 56.1 1.6 
  Minimum bone mass (kg) 3.0 0.1 3.0 0.1 3.0 0.08 3.0 0.08 
  Water (%) 48.7 0.8 49.0 0.8 48.7 0.8 48.9 0.99 
Abdominal bioimpedance         
  Fat (%) 32.9 1.2 32.5 1.2 32.6 1.2 32.3 1.2 
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Figure 2.  
 
 
 
 
 
 
